Yondelis(trabectedin)
Yondelis (trabectedin) is a small molecule pharmaceutical. Trabectedin was first approved as Yondelis on 2007-09-17. It is used to treat leiomyosarcoma and liposarcoma in the USA. It has been approved in Europe to treat ovarian neoplasms and sarcoma. It is known to target nuclear receptor subfamily 1 group I member 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Yondelis
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trabectedin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| YONDELIS | Johnson & Johnson | N-207953 RX | 2015-10-23 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| yondelis | New Drug Application | 2024-12-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| leiomyosarcoma | — | D007890 | — |
| liposarcoma | — | D008080 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Trabectedin, Yondelis, Janssen Prods | |||
| 8895557 | 2028-01-07 | DP | |
HCPCS
Code | Description |
|---|---|
| J9352 | Injection, trabectedin, 0.1 mg |
Clinical
Clinical Trials
107 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 2 | 3 | 1 | — | 2 | 7 |
| Neoplasms | D009369 | — | C80 | 1 | 4 | 1 | — | — | 6 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | 2 | — | 1 | 4 |
| Liposarcoma | D008080 | — | — | — | 3 | 1 | — | — | 4 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | 1 | 1 | — | 1 | 3 |
| Leiomyosarcoma | D007890 | — | — | 1 | 1 | 1 | — | — | 3 |
| Fallopian tube neoplasms | D005185 | — | — | — | — | 1 | — | — | 1 |
| Peritoneal neoplasms | D010534 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 3 | 1 | — | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | — | — | — | 2 |
| Myxoid liposarcoma | D018208 | — | — | — | 2 | — | — | — | 2 |
| Neoplasms by site | D009371 | — | — | — | 2 | — | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 1 | — | — | — | 1 |
| Uterine neoplasms | D014594 | EFO_0003859 | C55 | — | 1 | — | — | — | 1 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | — | 1 | — | — | — | 1 |
| Female genital neoplasms | D005833 | — | — | — | 1 | — | — | — | 1 |
| Skin diseases | D012871 | — | L00-L99 | — | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Neoplasms by histologic type | D009370 | — | — | 1 | — | — | — | — | 1 |
| Connective and soft tissue neoplasms | D018204 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Trabectedin |
| INN | trabectedin |
| Description | Trabectedin is a tetrahydroisoquinoline alkaloid obtained from a Caribbean tunicate Ecteinascidia turbinata. Used for the treatment of soft tissue sarcoma and relapsed ovarian cancer. It has a role as an antineoplastic agent, a marine metabolite, an anti-inflammatory agent, an angiogenesis modulating agent and an alkylating agent. It is an organic heteropolycyclic compound, an azaspiro compound, an oxaspiro compound, a bridged compound, a lactone, a polyphenol, an acetate ester, a hemiaminal, an organic sulfide, a tertiary amino compound and an isoquinoline alkaloid. |
| Classification | Small molecule |
| Drug class | ecteinascidin derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4 |
Identifiers
| PDB | — |
| CAS-ID | 114899-77-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL450449 |
| ChEBI ID | 84050 |
| PubChem CID | 108150 |
| DrugBank | DB05109 |
| UNII ID | ID0YZQ2TCP (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NR1I2
NR1I2
Organism
Homo sapiens
Gene name
NR1I2
Gene synonyms
PXR
NCBI Gene ID
Protein name
nuclear receptor subfamily 1 group I member 2
Protein synonyms
Orphan nuclear receptor PAR1, Orphan nuclear receptor PXR, Pregnane X receptor, Steroid and xenobiotic receptor, SXR
Uniprot ID
Mouse ortholog
Nr1i2 (18171)
nuclear receptor subfamily 1 group I member 2 (O54915)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,431 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,232 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use